Liraglutide
Metabolic Dysfunction-Associated Steatotic Liver Disease
Explore 131 assets in Metabolic Dysfunction-Associated Steatotic Liver Disease →Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Affiliated Hospital of Nantong University
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06501326CT.gov Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease | — | Unknown | — | — | — |
NCT05779644CT.gov Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus | — | Unknown | — | — | — |
NCT02147925CT.gov Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects | — | Completed | — | — | — |
NCT03068065CT.gov Antidiabetic Effects on Intrahepatic Fat | — | Completed | — | — | — |
NCT02654665CT.gov Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Dysfunction-Associated Steatotic Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Liraglutide (this asset) | Affiliated Hospital of Nantong University | Approved | BB · 68 |
| Dapagliflozin | Post Graduate Institute of Medical Education and Research, Chandigarh | P4 | BBB |
| Metformin | Xiqiao Zhou | P4 | BBB |
| Exenatide | Fudan University | P4 | BBB |
| Empagliflozin | Justin Ryder | P4 | BBB |
| Pioglitazone | Badr University | P4 | BBB |
| Tirzepatide | Regeneron Pharmaceuticals | P3 | BBB |
| Clesacostat | Columbia University | P2 | BB |
| Ervogastat | Pfizer | P2 | BB |
+42 more in the Metabolic Dysfunction-Associated Steatotic Liver Disease cohort
Other indications for Liraglutide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Disease | — | P4 | A · 84 |
| Type 1 Diabetes Mellitus | — | P4 | BBB · 79 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 79 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Liraglutide in Metabolic Dysfunction-Associated Steatotic Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/liraglutide-metabolic-dysfunction-associated-steatotic-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →